Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein

Thrombosis and Haemostasis

Volumn 81, Issue 5, 1999, Pages 748-757

  Merrill, Joan T ^a   Zhang, Hong Wei ^a   Shen, Christine ^a   Butman, Bryan T ^b   Jeffries, Eddie P ^b   Lahita, Robert G ^a   Myones, Barry L ^c  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Perlmmune Inc   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; COMPLEMENT COMPONENT C4B; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTEIN S;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN IMMOBILIZATION; PROTEIN PURIFICATION; THROMBOSIS;

EID: 0032940243     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614566     Document Type: Article

References (75)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheum 1986; 13: 486-9.
2. Alarcon-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheum 1989; 16: 762-7.
3. Boey ML, Colaco CB, Gharavi AE. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Brit Med. J 1983; 287: 1021-3.
4. Buchanen RC, Wardlow JR, Riglar A. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheum 1989; 16: 757-61.
5. Harris EN. Serologic detection of antiphospholipid antibodies. Stroke 1992; 23: SI3.
6. Bevers EM, Galli M, Barbui T. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
7. Oosting JD, Derksen RHWM, Bobbink IWG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S - an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25.
8. 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
9. Triplett DA. Antiphospholipid Antibodies: proposed mechanisms of action. Am J Reprod Immunol 1992; 28: 211-5.
10. Malia RG, Kitchen S, Graves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Brit J Haem 1990; 76: 101-7.
11. Killeen AA, Meyer KC, Vogt JC, Edson JR. Kallikrein inhibition and C1-esterase inhibitor levels in patients with the lupus inhibitor. Am J Clin Path 1987; 88: 223-8.
12. Sorice M, Arcieri P, Griggi T, Circella A, Misas R, Lenti L, Di Nucci GD. Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Thromb Haemost 1996; 75: 555-9.
13. Amiral J, Larrivaz I, Cluzeau D, Adam M. Standardization of immunoassays for antiphospholipid antibodies with beta 2 GP1 and role of other phospholipid cofactors. Thromb Haemost 1994; 24: 191-203.
14. Qamar T, Levy RA, Sammaritano L, Gharavi AE, Lockshin MD. Characteristics of high titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. Arth Rheum 1990; 33: 501-4.
15. Merrill JT, Rivkin E, Shen C, Lahita RG. Cloning of a gene for apolipoprotein A1 using serum from a patient with systemic lupus. Arth Rheum 1995; 38: 1655-9.
16. Viard JP, Amoura Z, Bach JF. Anti-beta 2 glycoprotein I antibodies in systemic lupus erythematosus: a marker of thrombosis associated with a circulating anticoagulant. Comptes Rend L'Acad Sci 1995; 313: 607-12.
17. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60.
18. Marciniak E, Romond E. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32.
19. Tsakiris DA, Settas L, Makris PC, Marbet CA. Lupus anticoagulant, antiphospholipid antibodies and thrombophilia. Relation to protein C - protein S - thrombomodulin. J Rheum 1990; 17: 705-7.
20. Amer L, Kisiel W, Searles R, Williams RC Jr. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 1990; 57: 247-58.
21. Freyssinet JM, Wiesel ML, Gauchy J. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity - a mechanism for thrombosis. Thromb Haemost 1986; 55: 309-13.
22. Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant (letter). N Eng J Med 1986; 314: 11934.
23. Carreras LO, Forastiero RR. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis 1996; 26: 340-57.
24. Cariou R, Tobelem G, Belluci S. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells, inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988; 60: 54-8.
25. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibtion of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
26. Esmon NL, Smirnov MD, Esmon CT. Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemost 1997; 78: 79-82.
27. Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falco C. Activated protein C resisitance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997; 130: 202-8.
28. Bokarewa MI, Bremme K, Falk G, Sten-Linder M, Egberg N, Blombäck M. Studies on phospholipid antibodies, APC-resistance and associated mutation in the coagulation factor V gene. Thromb Res 1995; 78: 193-200.
29. Bokarewa MI, Blombäck M. Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis. Semin Hematol 1997; 34: 235-43.
30. Bokarewa MI, Blombäck M, Bremme K. Phospholipid antibodies and resistance to activated protein C in women with thrombophilia. Blood Coagul Fibrinolysis 1995; 6: 417-22.
31. Bengtsson A, Zoller B, de Frutos PG, Dahlback B, Sturfelt G. Factor V: Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus. Lupus 1996; 5: 598-601.
32. Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO. Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies. Blood Coagul Fibrinolysis 1996; 7: 702-4.
33. Moreb J, Kitchens CS. Acquired functional protein S deficiency, cerebral venous thrombosis and coumarin skin necrosis in association with antiphospholipid syndrome: report of two cases. Am J Med 1989; 87: 207-10.
34. Sthoeger ZM, Sthoeger D, Mellnick SD. Transient anticardiolipin antibodies, functional protein S deficiency, and deep vein thrombosis. Am J Hem 1991; 36: 206-7.
35. Ruiz Arguelles CJ, Ruiz Arguelles A, Alarcon-Segovia D. Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4b-Binding Protein associates with recent history of venous thromboses, antiphospholipid antibodies and the antiphospholipid syndrome. J Rheum 1991; 10: 552-8.
36. Wattiaux MJ, Herve R, Robert A, Cabane J, Housset B, Imbert JC. Coumarin-induced skin necrosis associated with acquired protein S deficiency and antiphospholipid antibody syndrome. Arth Rheum 1994; 37: 1096-1100.
37. Amster MS, Conway J, Zeid M, Pincus S. Cutaneous necrosis resulting from protein S deficiency and increased antiphospholipid antibody in a patient with systemic lupus erythematosus. J Am Acad Derm 1993; 29: 853-7.
38. Ginsberg JS, Demers C, Brill-Edwards P, Bona R, Johnston M, Wong A, Denburg JA. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus. Am J Med 1995; 98: 379-83.
39. Parke AL, Weinstein RE, Bona RD. The thrombotic diathesis associated with the presence of antiphospholipid antibodies may be due to low levels of free protein S. Am J Med 1992; 93: 49-56.
40. Forastiero RR, Kordich L, Basilotta E, Carreras LO. Differences in protein S and C4b-binding protein levels in different groups of patients with the antiphospholipid antibodies. Blood Coag Fibrinolysis 1994; 5: 606-19.
41. Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - a crucial role for acquired free protein S deficiency. Thromb Haemost 1996; 76: 190-4.
42. Reverter JC, Tassies D, Font J, Monteagudo J, Escolar G, Ingelmo M, Ordinas A. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 1996; 16: 1319-26.
43. Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemost 1996; 76: 689-91.
44. Comp PC, Doray D, Patton D. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-8.
45. Scharfstein J, Perreira A, Gigli I, Nussenzweig V. Human C4-binding protein. Isolation and characterization. J Exp Med 1978; 148: 207-22.
46. Taylor FB Jr, Dahlback B, Chang AC, Lockhart MS, Hatanaka K, Peer G, Esmon CT. Role of free protein S and C4b Binding Protein in regulating the coagulant response to Escherichia coli. Bood 1995; 86: 2642-52.
47. 2-glycoprotein I inhibit the interaction between protein S and C4b-Binding Protein? Thromb Haemost 1993; 64: 930 (abs).
48. 2-glycoprotein I and human monoclonal anticardiolipin antibody on the protein S/C4b-Binding Protein system. Lupus 1997; 6: 358-64.
49. 2-glycoprotein I (Apo H). Evaluation of normal vs. lupus (SLE) plasma. Clin Chem 1993; 39: 6-9.
50. Griffin JH, Gruber A, Fernandez JA. Reevaluation of total, free and bound protein S and C4b-Binding Protein levels in plasma anticoagulated with citrate or hirudin. Blood 1992; 9: 3200-11.
51. Dahlback B, Frohm B, Nelsestuen G. High affinity interaction between C4b-Binding Protein and vitamin K-dependent protein S in the presence of calcium. Suggestion of a third component in blood regulating the interaction. J Biol Chem 1990; 256: 16082-7.
52. Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-Binding Protein during pregnancy and oral contraception. Brit J Haem 1988; 68: 437-43.
53. Garcia de Frutos PG, Alim RIM, Hardig Y, Zoller B, Dahlbäck B. Differential regulation of and chains of C4b-Binding Protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84: 815-22.
54. Sanchez-Corrace P, Criado Garcia O, Rodriguez de Cordoba S. Isoforms of human C4b Binding Protein I. Molecular basis for the C4BP isoform pattern and its variation in human plasma. J Immunol 1995; 155: 4030-6.
55. Criado Garcia O, Sanchez-Corral P, Rodriguez de Cordoba S. Isoforms of human C4b-Binding Protein II. Differential modulation of the C4BPA and C4BPB genes by acute phase cytokines. J Immunol 1995; 155: 4036-44.
56. Barnum SR, Dahlbäck B. C4b-Binding Protein, a regulatory component of the classical pathway of complement, is an acute-phase protein and is elevated in systemic lupus erythematosus. Complement Inflamm 1990; 7: 71-7.
57. D'Angelo A, Vigano-D'Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation. J Clin Invest 1988; 81: 1445-54.
58. Hesselvik JF, Malm J, Dahlbäck B, Blombäck M. Protein C, Protein S and C4b-Binding Protein in severe infection and septic shock. Thromb Haemost 1991; 65: 126-9.
59. Matsuda J, Gohchi K, Gotoh M, Tsukamoto M, Saitoh N. Plasma concentrations of total/free and functional protein S are not decreased in systemic lupus erythematosus patients with lupus anticoagulant and/or antiphospholipid antibodies. Annals Hematol 1994; 69: 311-5.
60. Kristenson J, Wetzel RA, Zack BF. The Complement Control Superfamily. J Immunol 1986; 136: 3407-11.
61. 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
62. Canfield WM, Kisiel W. Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease. J Clin Invest 1982; 70: 1260-6.
63. Brighton TA, Hogg PJ, Dai YP, Murray BH, Chong BH, Chesterman CN. Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol 1996; 93: 185-94.
64. Matsuda J, Wakasugi K, Saitoh N, Tsukamoto M, Miyajima Y, Kazama M, Asami K, Hashimoto M. Low beta 2-glycoprotein I levels in patients with disseminated intravascular coagulation [letter]. Am J Hematol 1993; 42: 234-5.
65. McNally T, Mackie IJ, Machin SJ, Isenberg DA. Elevated levels of beta 2 glycoprotein-I (beta 2 GPI) in antiphospholipid sundrome are due to increased amounts of beta 2 GPI in association with othe plasma constituents. Blood Coag Fibrinolysis 1995 6: 411-46.
66. Cevallos R, Darnige L, Arvieux J, Veyssier P, Gruel Y. Antiphospholipid and anti-beta 2 glycoprotein I antibodies in monozygotic twin sisters. J Rheum 1994; 21: 1970-1.
67. Vlachoyiannopoulos PG, Krilis SA, Hunt JE, Manoussakis MN, Moutsopoulos HM. Patients with anticardiolipin antibodies with and without antiphospholipid syndrome: their clinical features and beta 2-glycoprotein I plasma levels. Eur J Clin Invest 1992; 22: 482-7.
68. Matsuda J, Gohchi K, Kawasugi K, Gotoh M, Saitoh N, Tsukamoto M. Inhibitory activity of anti-beta 2-glycoprotein I antibody on factor Va degradation by activated protein C and its cofactor protein S. Am J Hematol 1995; 49: 89-91.
69. Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO. Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies. Blood Coag & Fibrinolysis 1996; 7: 7024.
70. Kamboh MI, Wagenknecht DR, McIntyre JA. Heterogeneity of the apolipoprotein H*3 allele and its role in affecting the binding of apolipoprotein H (beta 2-glycoprotein I) to anionic phospholipids. Hum Genet 1995; 95: 385-8.
71. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haem 1992; 67: 549-53.
72. Sellar GC, Keane J, Mehdi H, Peeples ME, Browne N, Whitehead AS. Characterization and acute phase modulation of canine apolipoprotein H (beta 2-glycoprotein I). Biochem Biophys Res Commun 1993; 191: 1288-93.
73. Mehdi H, Nunn M, Steel DM, Whitehead AS, Perez M, Walker L, Peeples ME. Nucleotide sequence and expression of the human gene enoding apolipoprotein H (beta 2-glycoprotein I). Gene 1991; 108: 293-8.
74. 2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus 4: 1995; S13-17.
75. 2-GP1 using synthetic peptides. Lupus 1995; 4: S7-11.